24/7 Market News Snapshot 30 Jan 2024
DENVER, Colo., Jan. 30, 2024 (247marketnews.com)- The following companies published announcements or are trading higher on higher-than-usual volume; Iterum Therapeutics PLC (NASDAQ:ITRM), Pixelworks Inc (NASDAQ:PXLW), Motus GI Holdings Inc (NASDAQ:MOTS), Rail Vision Ltd (NASDAQ:RVSN), Petros Pharmaceuticals Inc (NASDAQ:PTPI), and Kura Oncology Inc (NASDAQ:KURA).
News
NASDAQ-listed Agape ATP Unveils Expansion Plans and Green Initiatives at Opening Bell Ringing Ceremony- Agape ATP (NASDAQ:ATPC) is trading at $0.94, up $0.43 (+83.88%), on 22.9M shares traded.
The event held marks a significant milestone for ATPC and was attended by the Speaker of the Dewan Rakyat, YB Tan Sri Dato’ (Dr.) Johari Bin Abdul; Representing the Honourable Minister of Domestic Trade and Cost of Living YB Datuk Armizan Bin Mohd Ali is Senior Director, Trade, Distribution, and Business Sector, YBhg. Dato’ Rohaizi Bin Bahari; Chairman of SIRIM, YBhg. Datuk Ir (Dr) Khairol Nuar Mohamad Tawi; the NASDAQ ASEAN Investor Relations and IPO Director, Mr. Hiren Krishnani; and guests and business partners from Japan, Australia, Thailand, Singapore, Germany, the United States of America, China, Indonesia, and Taiwan.
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections- Iterum Therapeutics (NASDAQ:ITRM) is trading at $1.99, up $0.25 (+14.37%), on 16.5M shares traded.
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound – sulopenem – a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Website: www.iterumtx.com
Walt Disney Studios and Pixelworks Enter into a First of its Kind Multi-Year Agreement to Expand Reach of TrueCut Motion Technology- Pixelworks (NASDAQ:PXLW) is trading at $2.306, up $0.826 (+55.79%), on 14.4M shares traded.
Pixelworks, Inc. provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services. Pixelworks’ TrueCut Motion ecosystem allows filmmakers to create visually stunning motion, scene by scene while ensuring the director’s intent is precisely delivered in cinemas or home theaters.
Website: www.pixelworks.com
Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation- Motus GI (NASDAQ:MOTS) is trading at $0.99, up $0.0558 (+5.97%), on 8.4M shares traded.
Pixelworks, Inc. provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services. Pixelworks’ TrueCut Motion ecosystem allows filmmakers to create visually stunning motion, scene by scene while ensuring the director’s intent is precisely delivered in cinemas or home theaters.
Website: www.pixelworks.com
Rail Vision Reveals its Next Generation AI Computer for Railway Safety and Accident Prevention- Rail Vision (NASDAQ:RVSN) is trading at $21.57, up $6.88 (+46.83%), on 7.4M shares traded.
We’ve been covering this since its EU approval news, when it was at $2.51.
Rail Vision is a technology company that is seeking to revolutionize railway safety and the data-related market. The Company has developed cutting-edge, artificial intelligence based, industry-leading technology specifically designed for railways. The Company has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operators. Rail Vision believes that its technology will significantly increase railway safety around the world, while creating significant benefits and adding value to everyone who relies on the train ecosystem: from passengers using trains for transportation to companies that use railways to deliver goods and services. In addition, the company believes that its technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality.
Website: https://www.railvision.io/
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia- Kura Oncology (NASDAQ:KURA) is trading at 20.56, up $1.96 (+10.54%), on 3.8M shares traded.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Kura is currently enrolling patients in a Phase 2 registration-directed trial of ziftomenib in NPM1-m R/R AML (KOMET-001). The Company is also conducting a series of studies to evaluate ziftomenib in combination with current standards of care, beginning with ven/aza and 7+3 in NPM1-m and KMT2A-r newly diagnosed and R/R AML (KOMET-007). Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with cabozantinib in clear cell renal cell carcinoma and adagrasib in KRASG12C-mutated non-small cell lung cancer (FIT-001).
Website www.kuraoncology.com
We’ve been covering this since its EU approval news, when it was at $2.51.
This morning’s momentum movers include;
Agrify (NASDAQ:AGFY) is trading at $0.80, up $0.2931 (+57.82%), on 19.8M shares traded.
Agrify is a leading provider of innovative cultivation and extraction solutions for the cannabis industry, bringing data, science, and technology to the forefront of the market. Our proprietary micro-environment-controlled Vertical Farming Units (VFUs), enable cultivators to produce the highest quality products with unmatched consistency, yield, and ROI (return on investment) at scale. Our comprehensive extraction product line, which includes hydrocarbon, ethanol, solventless extraction, post-processing, and lab equipment, empowers producers to maximize the quantity and quality of extract required for premium concentrates.
Website: http://www.agrify.com.
Petros Pharmaceuticals (NASDAQ:PTPI) is trading at $1.54, up $0.17 (+12.40%), on 5.4M shares traded.
Petros Pharmaceuticals is committed to the goal of becoming a leading innovator in the emerging self-care market driving expanded access to key prescription pharmaceuticals as Over-the-Counter treatment options. Currently, Petros is pursuing increased access for its flagship prescription ED therapy, STENDRA, via potential OTC designation. If ultimately approved by the FDA for OTC access, STENDRA may be the first in its class to achieve this marketing status, also establishing company know how as a proven platform for other prospective prescription therapeutics.
CONTACT:
24/7 Market News
24/7 MARKET NEWS, INC Disclaimer
24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.
Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.
Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.
Connect with 24/7 Market News:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.